Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
CONCORD, Calif., March 26, 2024--Cerus Corporation (Nasdaq: CERS) today announced that the U.S. Food and Drug Administration (FDA) has granted approval of 12-month shelf life for INTERCEPT Platelet Processing Sets, from the date of manufacture, effective immediately. This approval extends the set shelf life by six months from the existing six-month shelf life that took effect following a set component change last year. All INTERCEPT Platelet Processing Sets in both customer and Cerus inventories
CONCORD, Calif., March 19, 2024--Cerus Corporation (Nasdaq: CERS) today announced positive topline results for ReCePI, a pivotal Phase 3 clinical trial of pathogen reduced INTERCEPT Red Blood Cells (INTERCEPT RBCs) transfused to complex cardiac surgery patients. The trial met its primary efficacy endpoint, demonstrating non-inferiority for INTERCEPT RBCs compared to conventional RBCs as measured by the incidence of acute kidney injury (AKI) following transfusion of study RBCs. AKI is a sensitive
On March 14, 2024, William Greenman, President and Chief Executive Officer of Cerus Corp (NASDAQ:CERS), sold 125,926 shares of the company, according to a recent SEC Filing.
Cerus Corp (NASDAQ:CERS), a company specializing in the field of blood transfusion safety with its innovative INTERCEPT Blood System, has reported an insider transaction involving its Chief Operating Officer, Vivek Jayaraman.
It's been a good week for Cerus Corporation ( NASDAQ:CERS ) shareholders, because the company has just released its...
Full-Year 2024 Revenue Guidance Reiterated Amidst Sequential Revenue Growth
Cerus Corporation (NASDAQ:CERS) Q4 2023 Earnings Call Transcript March 5, 2024 Cerus Corporation reports earnings inline with expectations. Reported EPS is $-0.01 EPS, expectations were $-0.01. Cerus Corporation isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day ladies and […]
Cerus ( NASDAQ:CERS ) Full Year 2023 Results Key Financial Results Revenue: US$156.4m (down 3.5% from FY 2022). Net...
Q4 2023 Cerus Corp Earnings Call
CONCORD, Calif., March 05, 2024--Cerus Corporation (Nasdaq: CERS) today announced financial results for the fourth quarter and full year ended December 31, 2023.